Bioactive Fluorenes. Part I. Synthesis, Pharmacological Study and Molecular Docking of Novel Dihydrofolate Reductase Inhibitors Based-2,7-dichlorofluorene
Overview
Authors
Affiliations
In this study, a new series of 2,7-dichloro-4-(2-substituted-amino acetyl)fluorene derivatives were synthesized, characterized and evaluated for their antimicrobial activity and screened for cytotoxic activity against human lung carcinoma (A-549) and human breast carcinoma (MCF-7) cell lines. Most of the synthesized compounds displayed significant activity against A-549 and MCF-7 cell lines when compared to 5-fluorouracil (5-FU), which was used as a reference drug. In addition, some of these reported novel compounds exhibited promising antibacterial and antifungal properties. A molecular docking study was performed to identify the mechanism of action of the synthesized compounds, which suggested binding interactions with the active sites of dihydrofolate reductase (DHFR).
An Intervention into the Diverse Utilities of Fluorenes: A Brobdingnagian Family.
Sreekumar A, Nair A, Raksha C, Swayamprabha S, Sivan A Top Curr Chem (Cham). 2024; 383(1):4.
PMID: 39680345 DOI: 10.1007/s41061-024-00485-6.
Marufa S, Rahman T, Rahman M, Rahman M, Khan S, Jahan R RSC Adv. 2024; 14(47):35198-35214.
PMID: 39497776 PMC: 11533417. DOI: 10.1039/d4ra04197f.
Anticancer Activity of Imidazolyl Gold(I/III) Compounds in Non-Small Cell Lung Cancer Cell Lines.
Galassi R, Sargentoni N, Renzi S, Luciani L, Bartolacci C, Pattabhi P Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338298 PMC: 11435220. DOI: 10.3390/ph17091133.
Dardir A, Casademont-Reig I, Balcells D, Ellefsen J, Espinosa M, Hazari N Organometallics. 2022; 40(14):2332-2344.
PMID: 35719693 PMC: 9199486. DOI: 10.1021/acs.organomet.1c00085.
Srdic M, Fessner N, Yildiz D, Glieder A, Spiertz M, Schwaneberg U Biomolecules. 2022; 12(2).
PMID: 35204652 PMC: 8961652. DOI: 10.3390/biom12020153.